About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Loss of Tumor Suppressor Opens a New Approach to Treat Breast Cancers

by Anjali Aryamvally on February 6, 2018 at 11:15 AM
Font : A-A+

Loss of Tumor Suppressor Opens a New Approach to Treat Breast Cancers

The loss of a specific tumor suppressor called retinoblastoma tumor suppressor in "triple-negative" breast cancer may provide a potential new approach to treat these cancers, shows study from the University of Arizona Cancer Center and Cancer Research UK. The study is published in the journal Cell.

Triple-negative breast cancers lack three receptors that can be targeted by drugs, which limits treatment options. Therapy can be "targeted" to be more specific to a patient's individual tumor profile, allowing for the delivery of "personalized" medicine. Currently, patients with triple-negative breast cancer are treated with radiation or chemotherapy, and lack options for targeted forms of treatment.

Advertisement


In response, the UA Cancer Center's Agnieszka Witkiewicz, MD, professor of pathology, and Erik Knudsen, PhD, professor of medicine at the UA College of Medicine - Tucson, analyzed unique features of triple-negative breast cancer to identify possible new approaches for treatment. Previous research from the group showed that about 20 to 30 percent of triple-negative breast cancers have lost the retinoblastoma (RB) tumor suppressor. Drs. Witkiewicz and Knudsen hypothesized that loss of this tumor suppressor in the subset of triple-negative breast cancers may provide a target for novel drugs.

A properly functioning RB tumor suppressor is present in normal breast cells and helps to maintain control over cell division. The loss of the RB tumor suppressor impairs one of the body's critical defense mechanisms against cancer formation.
Advertisement

"The lack of a personalized strategy to apply medicine based on specific features of a patient's tumor remains one of the seminal therapeutic challenges in the treatment of triple-negative breast cancer," said Dr. Witkiewicz. "Therefore, exploiting the loss of RB could represent a significant conceptual change in the way we consider treatment."

Three promising candidates emerged from a search for drugs that could target triple-negative breast cancers with the missing RB tumor suppressor. These tumors were susceptible to drugs that target PLK1 and AURK, proteins that are key drivers of cell division, and CHK1, a protein that is important for DNA replication. These proteins can be used as biomarkers, properties of a tumor that can be measured in blood to let doctors know more about a patient's cancer and how best to treat it.

The studies showed that triple-negative breast tumors lacking the RB tumor suppressor harbor increased levels of these biomarkers. Developing drugs that target PLK1, AURK and CHK1 could represent a strategy for treating the 20 to 30 percent of triple-negative breast cancer patients whose tumors do not respond to targeted treatments.

"Drugs that attack PLK1 or CHK1 wreak catastrophic damage on tumor cells that have lost RB," said Dr. Knudsen. "These studies underscore the importance of understanding fundamental features of tumor cell division and delineating how to target tumor-specific vulnerabilities with new drugs to exploit those events therapeutically."

The authors caution that these findings, while provocative, need further exploration. The group is planning studies to investigate PLK1, AURK and CHK1 inhibitors in clinical trials to test the effectiveness of drugs that target RB-deficient triple-negative breast cancer.

"A biomarker-driven clinical trial will be critical in advancing this concept from the laboratory to the clinic," said Dr. Witkiewicz.

Breast cancer is the most common type of cancer in the United States, with an estimated 252,710 diagnoses and 40,610 deaths in 2017, according to the National Cancer Institute. About 10 to 20 percent of breast cancers are triple-negative, and targeted treatments are necessary to decrease mortality associated with this aggressive form of the disease. Beyond triple-negative breast cancer, drugs that target RB-deficient tumors could have implications for other types of cancers in which tumors lose the RB tumor suppressor.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Cochlear Implants may Consequently Drive Hearing Loss
E-cigarettes Use Linked to Erectile Dysfunction
Memory Loss - Can it be Recovered?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Mastitis Breasts - Structures and Types Tumor Markers For Cancer Diagnosis and Prognosis Breast Lumps Breast Lumps-Screening Amyotrophic Lateral Sclerosis (ALS) Breast Enhancement Oil Acute Coronary Syndrome 

Recommended Reading
Biomarker That can Identify the Metastasis Risk for Triple Negative Breast Cancers
New molecular biomarkers that could identify the aggressive subset of TNBCs and more offer patients ...
Oxygen Bubble Burst to Make Breast Cancers More Susceptible to Radiation Therapy
Bursting oxygen-filled microbubbles in breast cancer makes tumors three times more sensitive to ......
Reason for Treatment-resistant Breast Cancers
Study shows how changes in the tumor coincide with when the patient's cancer stopped responding to ....
Some Breast Cancers Are Unresponsive to Immunotherapy
In some instances, tumor made up of half immune cells doesn't respond to a treatment that should ......
Acute Coronary Syndrome
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic red...
Amyotrophic Lateral Sclerosis (ALS)
Find out more about the degenerative disease- Amyotrophic lateral sclerosis....
Breast Enhancement Oil
Breasts contain mammary glands which produce and secrete milk for feeding and nourishing babies. Tho...
Breast Lumps
Most breast lumps are caused by hormonal changes in a woman and may not be cancerous. Common causes ...
Breast Lumps-Screening
Breast lumps must never be neglected but instead be subjected to medical examination to rule out ......
Breasts - Structures and Types
Different stages of breast development in women and an in-depth look at the breast/bust and its ......
Mastitis
Mastitis is a common cause of tenderness, swelling and pain in breast, owing to inflammation in the ...
Tumor Markers For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use